TScan Therapeutics, Inc.

NasdaqGM:TCRX Stock Report

Market Cap: US$75.7m

TScan Therapeutics Management

Management criteria checks 2/4

TScan Therapeutics' CEO is Gavin MacBeath, appointed in Mar 2023, has a tenure of 3.08 years. total yearly compensation is $2.80M, comprised of 23.7% salary and 76.3% bonuses, including company stock and options. directly owns 0.083% of the company’s shares, worth $62.71K. The average tenure of the management team and the board of directors is 2.3 years and 3 years respectively.

Key information

Gavin MacBeath

Chief executive officer

US$2.8m

Total compensation

CEO salary percentage23.74%
CEO tenure3.1yrs
CEO ownership0.08%
Management average tenure2.3yrs
Board average tenure3yrs

Recent management updates

Recent updates

TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025

Mar 07

TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting

Feb 10

Does TScan Therapeutics (NASDAQ:TCRX) Have A Healthy Balance Sheet?

Nov 06
Does TScan Therapeutics (NASDAQ:TCRX) Have A Healthy Balance Sheet?

TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology

Aug 26

Subdued Growth No Barrier To TScan Therapeutics, Inc.'s (NASDAQ:TCRX) Price

Mar 23
Subdued Growth No Barrier To TScan Therapeutics, Inc.'s (NASDAQ:TCRX) Price

Is TScan Therapeutics (NASDAQ:TCRX) Using Too Much Debt?

Feb 17
Is TScan Therapeutics (NASDAQ:TCRX) Using Too Much Debt?

TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported, And Analysts Assigned A US$10.75 Price Target

Mar 11
TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported, And Analysts Assigned A US$10.75 Price Target

TScan Therapeutics GAAP EPS of -$0.63 beats by $0.13, revenue of $4.05M beats by $1.05M

Aug 10

TScan Therapeutics appoints Debora Barton as Chief Medical Officer

Jul 07

Here's Why We're Watching TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Situation

May 22
Here's Why We're Watching TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Situation

Will TScan Therapeutics (NASDAQ:TCRX) Spend Its Cash Wisely?

Jan 17
Will TScan Therapeutics (NASDAQ:TCRX) Spend Its Cash Wisely?

We're Keeping An Eye On TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Rate

Oct 18
We're Keeping An Eye On TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Rate

CEO Compensation Analysis

How has Gavin MacBeath's remuneration changed compared to TScan Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025US$3mUS$665k

-US$130m

Sep 30 2025n/an/a

-US$143m

Jun 30 2025n/an/a

-US$137m

Mar 31 2025n/an/a

-US$131m

Dec 31 2024US$2mUS$620k

-US$127m

Sep 30 2024n/an/a

-US$111m

Jun 30 2024n/an/a

-US$104m

Mar 31 2024n/an/a

-US$97m

Dec 31 2023US$3mUS$545k

-US$89m

Sep 30 2023n/an/a

-US$88m

Jun 30 2023n/an/a

-US$82m

Mar 31 2023n/an/a

-US$73m

Dec 31 2022US$1mUS$450k

-US$66m

Sep 30 2022n/an/a

-US$62m

Jun 30 2022n/an/a

-US$61m

Mar 31 2022n/an/a

-US$57m

Dec 31 2021US$1mUS$400k

-US$49m

Sep 30 2021n/an/a

-US$42m

Jun 30 2021n/an/a

-US$34m

Mar 31 2021n/an/a

-US$29m

Dec 31 2020US$533kUS$350k

-US$26m

Compensation vs Market: Gavin's total compensation ($USD2.80M) is above average for companies of similar size in the US market ($USD622.46K).

Compensation vs Earnings: Gavin's compensation has increased whilst the company is unprofitable.

CEO

Gavin MacBeath (55 yo)

3.1yrs
Tenure
US$2,801,450
Compensation

Dr. Gavin MacBeath, Ph D., serves as CEO & Director of TScan Therapeutics, Inc. from May 24, 2023 and served as its Interim Principal Financial Officer since July 21, 2023 until 2023. Dr. MacBeath was Acti...

Leadership Team

NamePositionTenureCompensationOwnership
Gavin MacBeath
CEO & Director3.1yrsUS$2.80m0.083%
$ 62.7k
Jason Amello
CFO, Treasurer2.3yrsUS$1.28m0%
$ 0
Chrystal Louis
Chief Medical Officer2yrsUS$1.61m0%
$ 0
Stephen Elledge
Co-Founder & Chairman of Scientific Advisory Boardno datano datano data
Tomasz Kula
Co-Founder & Member of Advisory Boardno datano datano data
Zoran Zdraveski
Chief Legal & Strategy Officer and Company Secretary4.6yrsUS$1.58m0.0078%
$ 5.9k
Ann Hargraves
Chief Human Resources Officer6.3yrsno datano data
Shrikanta Chattopadhyay
Senior VP & Head of Translational Medicine3.3yrsno datano data
Ray Lockard
Chief Manufacturing & Quality Officer2.3yrsno datano data
Jim Murray
Chief Development Operations Officer2.2yrsno datano data
Cagan Gurer
Senior Vice President of Discovery2.2yrsno datano data
Stephen Camiolo
Senior Vice President of Market Access1.1yrsno datano data
2.3yrs
Average Tenure
55yo
Average Age

Experienced Management: TCRX's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Gavin MacBeath
CEO & Director2.9yrsUS$2.80m0.083%
$ 62.7k
Stephen Elledge
Co-Founder & Chairman of Scientific Advisory Boardno datano datano data
Tomasz Kula
Co-Founder & Member of Advisory Boardno datano datano data
Malcolm Brenner
Member of Advisory Boardno datano datano data
Stephen Biggar
Independent Chair of the Board5.1yrsUS$162.23k0%
$ 0
Katina Dorton
Independent Director5.1yrsUS$139.11k0%
$ 0
Garry Nicholson
Independent Director1.8yrsUS$125.36k0%
$ 0
Barbara Klencke
Independent Director3yrsUS$145.78k0.12%
$ 88.2k
Kai Wucherpfennig
Member of Advisory Boardno datano datano data
Robert Woods
Independent Director2.3yrsUS$125.27k0%
$ 0
Gabriela Gruia
Independent Director4.9yrsUS$129.12k0%
$ 0
3.0yrs
Average Tenure
67.5yo
Average Age

Experienced Board: TCRX's board of directors are considered experienced (3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/26 12:27
End of Day Share Price 2026/04/24 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

TScan Therapeutics, Inc. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew FeinH.C. Wainwright & Co.
Andres MaldonadoH.C. Wainwright & Co.
Christopher HowertonJefferies LLC